摘要
背景:阿尔茨海默病(AD)患者对胆碱酯酶抑制剂(CHI)治疗的反应不同,个体特异性反应是否直接影响到疗养院安置时间(NHP)。 目的:探讨6个月对CHI的反应与住院治疗的关系。 方法:采用前瞻性、观察性、多中心研究的方法,对881例门诊患者在CHI治疗开始时(基线)进行临床诊断和简易精神状态评分(10-26分),采用认知、整体和日常生活活动能力量表(ADL)进行评定,每半年一次,记录进NHP的日期。 结果:在本研究中,213例(24%)患者入院,从基线(AD诊断)到NHP的平均±标准差时间(AD)为20.8±9.3个月,经过6个月的CHI治疗后,改善或未改变的患者对NHP的治疗时间比恶化的患者长,认知反应延长3个月(p=0.022),整体反应延长4个月(p=0.004),基础不良反应6个月。3个量表均有反应(p<0.001)和8个月(p<0.001),改善组与未变化组在任何量表上均无显着性差异(P>0.05)。 结论:对CHI有阳性短期反应的患者可期望在家中待3~8个月,这些发现强调了综合临床检查的重要性,包括各种评估量表,以评估治疗效果并提供更准确的预后。
关键词: 阿尔茨海默病,胆碱酯酶抑制剂,治疗效果,日常生活能力,认知,养老院安置,预测因子,统计模型。
Current Alzheimer Research
Title:Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
Volume: 15 Issue: 10
关键词: 阿尔茨海默病,胆碱酯酶抑制剂,治疗效果,日常生活能力,认知,养老院安置,预测因子,统计模型。
摘要: Background: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer’s disease (AD). Whether the individual-specific response directly affects time to nursing home placement (NHP) was not investigated.
Objective: We examined the relationship between the 6-month response to ChEI and institutionalization.
Methods: In a prospective, observational, multicenter study, 881 outpatients with a clinical AD diagnosis and a Mini-Mental State Examination score of 10-26 at the start of ChEI therapy (baseline) were included. The participants were evaluated using cognitive, global, and activities of daily living (ADL) scales at baseline and semiannually over 3 years. The date of NHP was recorded.
Results: During the study, 213 patients (24%) were admitted to nursing homes. The mean ± standard deviation time from baseline (AD diagnosis) to NHP was 20.8 ± 9.3 months. After 6 months of ChEI treatment, the improved/unchanged individuals had longer time to NHP than those who worsened. The prolonged time to NHP was 3 months for cognitive response (P=0.022), 4 months for global response (P=0.004), 6 months for basic ADL response (P<0.001), and 8 months for response in all three scales (P<0.001). No differences were detected between the improved and unchanged groups in any scales.
Conclusion: Patients who exhibit a positive short-term response to ChEI can expect to stay in their own home for 3-8 months longer. These findings underline the importance of a comprehensive clinical examination including various assessment scales to evaluate treatment response and provide a more accurate prognosis.
Export Options
About this article
Cite this article as:
Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement, Current Alzheimer Research 2018; 15 (10) . https://dx.doi.org/10.2174/1567205015666180507105326
DOI https://dx.doi.org/10.2174/1567205015666180507105326 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Editorial
Current Drug Therapy Nano Clinoptilolite: Highly Efficient Catalyst for the Synthesis of Chromene Derivatives Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Computer based Classification of MR Scans in First Time Applicant Alzheimer Patients
Current Alzheimer Research Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design Physical Exercise for the Treatment of Neuropsychiatric Disturbances in Alzheimer’s Dementia: Possible Mechanisms, Current Evidence and Future Directions
Current Alzheimer Research β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Prevalence and Predictors of Overweight and Obesity in Patients with Pituitary Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine